SAN FRANCISCO, August 21, 2017 /PRNewswire/ --
The global melanoma therapeutics market is expected
to reach USD 12.4 billion by 2025,
according to a new report by Grand View Research, Inc. Increasing
incidence of chronic diseases such as melanoma, skin cancer, and
skin allergies is an important driver of the market.
(Logo:
http://photos.prnewswire.com/prnh/20160524/371361LOGO )
According to CDC, over 71,943 people were affected by melanoma
in 2013. The American Cancer Society estimates that this number
will go up to 87,100 in 2017, thus highlighting the need for
melanoma drugs over the forecast period.
Increasing number of FDA approvals and introduction of novel
therapeutics with enhanced efficacy are also anticipated to present
growth opportunities. Within a period of 6 years, i.e., from 2011
to 2016, around eight biologics have been approved for the
treatment of this disease, which include Opdivo, Yervoy, Cotellic,
Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.
Companies are undertaking various R&D activities to find new
indications for existing products and development of innovative
molecules. For instance, in September
2014, the U.S. FDA approved patented drug Keytruda (Merck
& Co., Inc.) to treat metastatic melanoma, thereby extending
the therapeutic application of its product. This drug was initially
approved for treatment of non-small cell lung cancer.
Furthermore, many pharmaceutical companies in the U.S.,
Europe, and Asia Pacific are focusing on development of
new biologics. For instance, in March
2017, Daiichi Sankyo Company, Limited announced a
collaborative drug discovery project-Take a New challenge for Drug
discovery (TaNeDS)-to facilitate new drug development through
collaborations. Moreover, it entered into a strategic research
collaboration with AgonOX, Inc. to develop new immunotherapy drugs
for the immuno-oncology segment. Approval of novel products over
the forecast period is anticipated to boost market growth.
Browse full research report with TOC on
"Melanoma Therapeutics Market Analysis By Therapy, By
Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic,
Zelboraf, Imlygic, Generics), And Segment Forecasts, 2014 -
2025" at:
http://www.grandviewresearch.com/industry-analysis/melanoma-therapeutics-market
Further key findings from the report suggest:
- Targeted therapy segment is expected to show lucrative growth
owing to benefits such as low adverse effects and higher
efficiency
- Branded drugs held a dominant share of the industry because of
patent exclusivity
- Biologics, such as Opdivo and Cotellic, are expected to exhibit
lucrative growth over the forecast period owing to increase
adoption and advantages such improved therapeutic effects
- The patent for Yervoy will expire in 2022 in the U.S. and in
2020 in Europe. This is expected
to provide growth opportunities for new market entrants
- Asia Pacific is expected to
exhibit lucrative CAGR over the forecast period
- Key market players are increasing R&D efforts for discovery
and development of novel drugs for the treatment of melanoma
Browse related reports by Grand View Research:
- Kidney Cancer Drugs Market -
http://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market
- Biotechnology Reagents Market -
http://www.grandviewresearch.com/industry-analysis/biotechnology-reagent-market
- ePharmacies Market -
http://www.grandviewresearch.com/industry-analysis/epharmacies-market
- Biopharmaceutical Market -
http://www.grandviewresearch.com/industry-analysis/biopharmaceutical-market
Grand View Research has segmented the melanoma therapeutics
market on the basis of therapy, drugs, and region:
- Melanoma Therapeutics Therapy Outlook (Revenue, USD Million,
2014 - 2025)
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Melanoma Therapeutics Drugs Outlook (Revenue, USD Million,
2014 - 2025)
- Opdivo
- Yervoy
- Mekinist+Tafinlar
- Keytruda
- Cotellic
- Zelboraf
- Imlygic
- Generics
- Melanoma Therapeutics Regional Outlook (Revenue, USD
Million, 2014 - 2025)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Read Our Blog By Grand View Research:
http://www.grandviewresearch.com/blogs/healthcare
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company
provides syndicated research reports, customized research reports,
and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant
and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: http://www.grandviewresearch.com